Iterum Therapeutics plc - Ordinary Share (ITRM): Price and Financial Metrics


Iterum Therapeutics plc - Ordinary Share (ITRM)

Today's Latest Price: $1.20 USD

0.02 (-1.64%)

Updated Jul 8 4:00pm

Add ITRM to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 213 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

ITRM Stock Summary

  • Iterum Therapeutics plc's stock had its IPO on May 25, 2018, making it an older stock than only 4.47% of US equities in our set.
  • ITRM's price/sales ratio is 1,370.36; that's higher than the P/S ratio of 99.56% of US stocks.
  • Revenue growth over the past 12 months for Iterum Therapeutics plc comes in at -95.74%, a number that bests just 0.64% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to ITRM, based on their financial statements, market capitalization, and price volatility, are SCYX, CBMG, TOCA, INO, and ITCI.
  • ITRM's SEC filings can be seen here. And to visit Iterum Therapeutics plc's official web site, go to www.iterumtx.com.
ITRM Daily Price Range
ITRM 52-Week Price Range

ITRM Stock Price Chart Technical Analysis Charts


ITRM Price/Volume Stats

Current price $1.20 52-week high $7.65
Prev. close $1.22 52-week low $1.12
Day low $1.17 Volume 658,709
Day high $1.22 Avg. volume 579,734
50-day MA $2.49 Dividend yield N/A
200-day MA $2.96 Market Cap 21.42M

Iterum Therapeutics plc - Ordinary Share (ITRM) Company Bio


Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. The company is developing sulopenem, a penem anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of adults in uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. Iterum Therapeutics plc was founded in 2015 and is based in Dublin, Ireland.


ITRM Latest News Stream


Event/TimeNews Detail
Loading, please wait...

ITRM Latest Social Stream


Loading social stream, please wait...

View Full ITRM Social Stream

Latest ITRM News From Around the Web

Below are the latest news stories about Iterum Therapeutics plc that investors may wish to consider to help them evaluate ITRM as an investment opportunity.

The Daily Biotech Pulse: Novartis Settles Lawsuit For $678M, Sarepta In-Licenses Gene Therapy Pre-Treatment, Unity Biotech Outlines Second-Half Catalysts

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 1) AbbVie Inc (NYSE: ABBV ) ADC Therapeutics SA (NYSE: ADCT ) Affimed NV (NASDAQ: AFMD ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Akero Therapeutics Inc (NASDAQ: AKRO ) ( announced positive results for mid-stage study of NASH drug) Amgen, Inc. (NASDAQ: AMGN ) (reacted to a favorable court ruling on its Enbrel patent litigation) Aptinyx Inc (NASDAQ: APTX ) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP ) Crispr Therapeutics AG (NASDAQ: CRSP ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) Hologic, Inc. (NASDAQ: HOLX ) Legend Biotech Corp (NASDAQ: LEGN ) Liminal BioSciences Inc (NASDAQ: LMNL ) (announce...

Benzinga | July 2, 2020

The Daily Biotech Pulse: T2 Biosystems Launches COVID-19 Test, Akero Aces Midstage NASH Study, Aravive Added to Russell Indexes

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 30) ADC Therapeutics SA (NYSE: ADCT ) Akebia Therapeutics Inc (NASDAQ: AKBA ) Alterity Therapeutics Ltd (NASDAQ: ATHE ) ( announced agreement with the FDA regarding Phase 2 study of Parkinsonian disorder drug) Calliditas Therapeutics AB ADR (NASDAQ: CALT ) GENMAB A/S/S ADR (NASDAQ: GMAB ) - partner Seattle Genetics, Inc. (NASDAQ: SGEN ) announced positive results for antibody-drug conjugate for cervical cancer Halozyme Therapeutics, Inc. (NASDAQ: HALO ) Hologic, Inc. (NASDAQ: HOLX ) ( reacted to a positive analyst action) Legend Biotech Corp (NASDAQ: LEGN ) Meridian Bioscience, Inc. (NASDAQ: VIVO ) Mersana Therapeutics Inc (NASDAQ: MRSN ) Novavax...

Benzinga | July 1, 2020

Iterum Therapeutics executes $5M direct offering

Iterum Therapeutics (ITRM) inks agreements with institutional investors for the direct sale of 3,372,686 ordinary shares at $1.4825/share. Gross proceeds should be ~$5M.Buyers will also receive unregistered 5 1/2-year warrants to purchase up to 1,686,343 ordinary shares at $1.42. Net proceeds will fund the continued clinical development of sulopenem, working...

Seeking Alpha | June 30, 2020

Iterum Therapeutics Announces $5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

Iterum Therapeutics plc (ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral antibiotics to treat infections caused by multi-drug resistant pathogens in community settings, today announced that it has entered into definitive agreements with institutional investors for the purchase and sale of 3,372,686 of its ordinary shares at a purchase price of $1.4825 per ordinary share in a registered direct offering priced at-the-market under Nasdaq rules. The Company also agreed to issue to the investors unregistered warrants to purchase up to 1,686,343 ordinary shares in a concurrent private placement. The warrants have an exercise price of $1.42 per share, are exercisable immediately, and will expire five and one-half years following the date of issuance.

Yahoo | June 30, 2020

Iterum's sulopenem shows mixed results in pivotal trial

Iterum Therapeutics ([[ITRM]] -8.5%) announces uneven topline results from its Phase 3 SURE1 clinical trial evaluating sulopenem for the treatment of uncomplicated urinary tract infections (uUTI), achieving one primary endpoint but missing a related one. In a population of patients with baseline pathogens resistant to quinolones, sulopenem demonstrated superiority to ciprofloxacin (cipro)...

Seeking Alpha | June 29, 2020

Read More 'ITRM' Stories Here

ITRM Price Returns

1-mo -28.14%
3-mo N/A
6-mo -70.15%
1-year -81.55%
3-year N/A
5-year N/A
YTD -73.33%
2019 -10.18%
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Continue Researching ITRM

Want to see what other sources are saying about Iterum Therapeutics plc's financials and stock price? Try the links below:

Iterum Therapeutics plc (ITRM) Stock Price | Nasdaq
Iterum Therapeutics plc (ITRM) Stock Quote, History and News - Yahoo Finance
Iterum Therapeutics plc (ITRM) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.9294 seconds.